Sung Ji Nam
Stock Analyst at Scotiabank
(2.82)
# 1,645
Out of 5,147 analysts
83
Total ratings
50.72%
Success rate
6.07%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $93.90 | -36.10% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $59.00 | +27.12% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $210.64 | +30.55% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $521.11 | +13.22% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $134.46 | -7.04% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $29.57 | +35.27% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $15.33 | +160.93% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $4.61 | +30.15% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.15 | +247.83% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.68 | +19.05% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $103.38 | -29.39% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $16.02 | -25.09% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $319.38 | +40.90% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $46.92 | +32.14% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $36.59 | +20.25% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $18.76 | +86.57% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $2.58 | +132.56% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.33 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $93.90
Upside: -36.10%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $59.00
Upside: +27.12%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $210.64
Upside: +30.55%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $521.11
Upside: +13.22%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $134.46
Upside: -7.04%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $29.57
Upside: +35.27%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $15.33
Upside: +160.93%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $4.61
Upside: +30.15%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.15
Upside: +247.83%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.68
Upside: +19.05%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $103.38
Upside: -29.39%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $16.02
Upside: -25.09%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $319.38
Upside: +40.90%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $46.92
Upside: +32.14%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $36.59
Upside: +20.25%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $18.76
Upside: +86.57%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $2.58
Upside: +132.56%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $15.33
Upside: -